Clinical Trial: An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517263) titled 'An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)' on April 01.

Brief Summary: This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).

Study Start Date: April 13

Study Type: INTERVENTIONAL

Condition: Cardiovascular Disease and Lipoprotein(a)

Intervention: DRUG: Pelacarsen (TQJ230)

pelacarsen 80mg s.c. monthly

Recruitment Status: RECRUITING

Sponsor: Novartis Pharmaceuticals

Published by HT Digital Content Se...